PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15723960-6 2005 In normotensive controls, midwall shortening increased from baseline during 2 microg x kg(-1) x min(-1) dobutamine by an average of 16+/-4.5% (P<0.01); a value of 2 standard deviations below this mean response was taken as the lower limit of normal. Dobutamine 104-114 CD59 molecule (CD59 blood group) Homo sapiens 96-102 19735400-6 2009 Both mean and maximum blood flow increased significantly in the anastomosed artery at dobutamine infusions of 4 and 6 microg x kg(-1) x min(-1) and this was accompanied by increased cardiac output. Dobutamine 86-96 CD59 molecule (CD59 blood group) Homo sapiens 136-142 18031577-7 2007 Dobutamine administration produced a rapid increase in heart rate (9.4 +/- 5.9 beats/min2). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 85-89 16550155-9 2006 Dobutamine is recommended when the cardiac index is less than 2.5 L x min(-1) x m(-2). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 70-76 17325594-4 2007 In group A patients, dobutamine was administered at a starting dose of 5 microg x kg(-1) x min(-1) increased to 10, 20 and 30 microg x kg(-1) x min(-1) to a maximum dose of 40 microg x kg(-1) x min(-1) at 3 min intervals until the target heart rate (THR, 85% of age predicted maximum heart rate) or other standard end point criteria were achieved. Dobutamine 21-31 CD59 molecule (CD59 blood group) Homo sapiens 91-97 17325594-7 2007 The mean dose of dobutamine infused in group A was significantly higher than in group B (36.2 vs. 23.5 microg x kg(-1) x min(-1), P<0.01). Dobutamine 17-27 CD59 molecule (CD59 blood group) Homo sapiens 121-127 10598598-6 1999 RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05). Dobutamine 9-19 CD59 molecule (CD59 blood group) Homo sapiens 72-78 11959654-5 2002 Demand-induced ischemia was produced with intravenous dobutamine (15 microg x kg(-1) x min(-1)) and 20% reduction in LAD flow for 20 min. Dobutamine 54-64 CD59 molecule (CD59 blood group) Homo sapiens 87-93 11465229-4 2001 After a resting Doppler echocardiogram, a dobutamine infusion was started at a rate of 5 microg x kg(-1) x min(-1) and increased to 30 microg x kg(-1) x min(-1) at 15-minute intervals. Dobutamine 42-52 CD59 molecule (CD59 blood group) Homo sapiens 107-113 10681485-6 2000 METHODS: Seventy five patients with previous myocardial infarction were studied in a low dose (up to 20 microg(-1) x kg(-1) x min(-1)) dobutamine stress echocardiography study. Dobutamine 135-145 CD59 molecule (CD59 blood group) Homo sapiens 126-132 12972869-5 2003 RESULTS: Compared with peak exercise, dobutamine infusion resulted in lower cardiac output (12 +/- 2 vs 16 +/- 4 l x min(-1), P < 0.0001), heart rates (163 +/- 7 vs 175 +/- 12 beats x min(-1), P < 0.0001), and systolic blood pressure (160 +/- 22 vs 185 +/- 20 mm Hg, P < or = 0.0001). Dobutamine 38-48 CD59 molecule (CD59 blood group) Homo sapiens 117-123 12972869-5 2003 RESULTS: Compared with peak exercise, dobutamine infusion resulted in lower cardiac output (12 +/- 2 vs 16 +/- 4 l x min(-1), P < 0.0001), heart rates (163 +/- 7 vs 175 +/- 12 beats x min(-1), P < 0.0001), and systolic blood pressure (160 +/- 22 vs 185 +/- 20 mm Hg, P < or = 0.0001). Dobutamine 38-48 CD59 molecule (CD59 blood group) Homo sapiens 187-193 10598598-6 1999 RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05). Dobutamine 9-19 CD59 molecule (CD59 blood group) Homo sapiens 168-174 10598598-6 1999 RESULTS: Dobutamine increased cardiac index (3.0+/-0.6 to 4.4+/-1.0 l x min(-1)m(-2), mean +/- SD; P < 0.05), splanchnic blood flow (from 0.8+/-0.2 to 1.0 + 0.2 l x min(-1)m(-2); P < 0.05), femoral blood flow (from 0.2+/-0.1 to 0.3+/-0.1 l x min(-1)m(-2); P < 0.05), and the arterial-gastric mucosal Pco2 gap (from 11.4+/-9.5 to 11.9+/-8.0 mmHg; P < 0.05). Dobutamine 9-19 CD59 molecule (CD59 blood group) Homo sapiens 168-174 10598598-7 1999 Dobutamine increased systemic oxygen consumption (from 132+/-14 to 146+/-13 ml x min(-1) x m(-2); P < 0.05) but not splanchnic or femoral oxygen consumption. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 81-87 10484566-7 1999 Therefore, we conclude that dobutamine can be used as a selective beta(1)-adrenoceptor agonist at dosages </=10 microg x kg(-1) x min(-1) in in vivo studies on human thermogenesis and lipid utilization. Dobutamine 28-38 CD59 molecule (CD59 blood group) Homo sapiens 133-139 10551583-3 1999 METHODS: One hundred patients received sequential 3-min infusions of dobutamine at 0-40 microg x kg(-1) x min(-1) immediately after cardiopulmonary bypass. Dobutamine 69-79 CD59 molecule (CD59 blood group) Homo sapiens 106-112 10551583-10 1999 Systemic vascular resistance initially increased with dobutamine 10 microg x kg(-1) x min(-1) and remained constant with larger doses. Dobutamine 54-64 CD59 molecule (CD59 blood group) Homo sapiens 86-92 10552089-8 1999 8+/-0.06 ml min(-1) g(-1) at rest and 1.48+/-0.15 ml min(-1) g(-1) during dobutamine stress. Dobutamine 74-84 CD59 molecule (CD59 blood group) Homo sapiens 53-59 10484566-2 1999 At 2.5, 5, and 10 microg x kg(-1) x min(-1), dobutamine induced significant increases in energy expenditure, lipid oxidation, and lipolysis. Dobutamine 45-55 CD59 molecule (CD59 blood group) Homo sapiens 36-42 10484566-3 1999 The beta(1)-adrenoceptor antagonist atenolol (bolus: 42.5 microg/kg, infusion: 1.02 microg x kg(-1) x min(-1)) blocked all dobutamine-induced effects on thermogenesis and lipid utilization. Dobutamine 123-133 CD59 molecule (CD59 blood group) Homo sapiens 102-108 9183605-5 1997 Most dobutamine stress protocols start at an infusion rate of 5 micrograms.kg-1.min-1 and increase to a peak dose of 40 or 50 micrograms.kg-1.min-1; to further increase heart rate, a bolus injection of 0.25-1.0 mg atropine is added. Dobutamine 5-15 CD59 molecule (CD59 blood group) Homo sapiens 80-85 10353179-9 1999 Comparing the wall motion score index at rest with the index after DSE 5 and 10 micrograms.kg-1.min-1 dobutamine and after HBO2, there was significant improvement (P < 0.005). Dobutamine 102-112 CD59 molecule (CD59 blood group) Homo sapiens 96-101 10353179-10 1999 Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005). Dobutamine 92-102 CD59 molecule (CD59 blood group) Homo sapiens 86-91 10353179-10 1999 Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005). Dobutamine 92-102 CD59 molecule (CD59 blood group) Homo sapiens 86-91 10353179-10 1999 Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005). Dobutamine 92-102 CD59 molecule (CD59 blood group) Homo sapiens 86-91 10353179-10 1999 Differences between DSE 5 micrograms.kg-1.min-1 dobutamine and DSE 10 micrograms.kg-1.min-1 dobutamine and between HBO2 and DSE 10 micrograms.kg-1.min-1 dobutamine were also significant (P < 0.005). Dobutamine 92-102 CD59 molecule (CD59 blood group) Homo sapiens 86-91 9597418-5 1998 Dobutamine was infused up to 40 mu.kg.l-1 min-1 in 3 min stages. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 42-47 10382089-4 1999 Dobutamine (up to 40 micrograms kg-1 min-1)-atropine (up to 1 mg) stress echocardiography in conjunction with stress-reinjection 201Tl SPET was performed for the evaluation of myocardial ischaemia in 90 patients with previous myocardial infarction who underwent coronary angiography. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 37-42 9386153-6 1997 After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001). Dobutamine 6-16 CD59 molecule (CD59 blood group) Homo sapiens 111-117 9386153-6 1997 After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001). Dobutamine 6-16 CD59 molecule (CD59 blood group) Homo sapiens 183-189 9386153-6 1997 After dobutamine infusion, blood flow increased less in contractile reserve-negative (0.63+/-0.38 mL x g(-1) x min(-1)) than in contractile reserve-positive (1.28+/-0.65 mL x g(-1) x min(-1)) and normal segments (1.93+/-0.83 mL x g(-1) x min(-1), P<.0001). Dobutamine 6-16 CD59 molecule (CD59 blood group) Homo sapiens 183-189 9386153-8 1997 Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001). Dobutamine 35-45 CD59 molecule (CD59 blood group) Homo sapiens 108-114 9386153-8 1997 Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001). Dobutamine 35-45 CD59 molecule (CD59 blood group) Homo sapiens 169-175 9386153-8 1997 Myocardial oxygen consumption with dobutamine increased less in contractile reserve-negative (0.060+/-0.013 min(-1)) than in contractile reserve-positive (0.077+/-0.016 min(-1)) and normal segments (0.092+/-0.024 min(-1), P<.0001). Dobutamine 35-45 CD59 molecule (CD59 blood group) Homo sapiens 169-175 9183619-7 1997 Dobutamine is infused at low rates of 2.5 to 20 micrograms.kg-1.min-1 to detect myocardial viability. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 64-69 8977994-11 1996 Dobutamine infusion increased heart rate (to about 190 x min-1 and CI by 30% in normovolemia and hypovolemia, while ITBV remained basically unchanged. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 57-62 9124918-4 1997 Dobutamine infusion was started at a rate of 5 microg x kg(-1) x min(-1) and increased to 10 and 20 microg x kg(-1) x min(-1) at 15-minute intervals. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 65-71 9043840-3 1997 AIMS: The present study aimed to assess the effects of non-beta-blocker antianginal therapy on dobutamine (up to 40 micrograms.kg-1.min-1)-atropine (up to 1 mg) stress. Dobutamine 95-105 CD59 molecule (CD59 blood group) Homo sapiens 132-137 8960434-6 1996 Dobutamine was progressively increased (5-40 micrograms.kg-1.min-1) and atropine was injected in 30 patients. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 61-66 8960434-8 1996 RESULTS: The mean peak dobutamine dose was 32 +/- 11 micrograms.kg-1.min-1. Dobutamine 23-33 CD59 molecule (CD59 blood group) Homo sapiens 69-74 8857434-5 1996 INTERVENTIONS: The effect of dobutamine infusion (6 mu g kg-1 min-1) on systemic and regional oxygen transport was studied in ten patients, with six patients serving as controls. Dobutamine 29-39 CD59 molecule (CD59 blood group) Homo sapiens 62-67 8829879-12 1996 VO2 increased more with dobutamine than with nitroprusside (from 138 +/- 14 to 149 +/- 20 ml min-1 m-2, P < 0.001, and from 131 +/- 14 to 138 +/- 17 ml min-1 m-2, P < 0.001, respectively). Dobutamine 24-34 CD59 molecule (CD59 blood group) Homo sapiens 155-160 8829879-13 1996 However, DO2 also increased more with dobutamine than with nitroprusside (from 531 +/- 186 to 702 +/- 274 ml min-1 m-2, P < 0.001, and from 523 +/- 107 to 610 +/- 122 ml min-1 m-2, P < 0.001, respectively). Dobutamine 38-48 CD59 molecule (CD59 blood group) Homo sapiens 109-114 8583814-3 1996 Dobutamine infusion was started at a rate of 5 micrograms.kg-1.min-1 and increased to 10 and 20 micrograms.kg-1.min-1 at 15-minute intervals. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 63-68 8857434-8 1996 Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 68-73 8857434-8 1996 Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 76-81 8857434-8 1996 Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 154-159 8857434-8 1996 Dobutamine increased cardiac output (3.2 +/- 0.6 vs 4.4 +/- 0.7 l x min-1 x min-2; P <0.05), splanchnic blood flow (0.68 +/- 0.28 vs 0.91 +/- 0.28 l x min-1 x m-2; p <0.05) and femoral blood flow (0.25 +/- 0.08 vs 0.32 +/- 0.11 l x min-1 x m-2; p <0.05). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 154-159 8857434-11 1996 Systemic oxygen consumption increased in response to dobutamine (141 +/- 11 vs 149 +/- 11 ml x min-1 x m-2; P <0.05) but did not change in the control group. Dobutamine 53-63 CD59 molecule (CD59 blood group) Homo sapiens 95-100 8881872-6 1995 RESULTS: Dobutamine increased heart rate (rest = 69 +/- 9 vs dobutamine = 138 +/- 13 beats.min-1; P < 0.01), whereas systolic blood pressure did not change significantly (rest = 136 +/- 15 vs dobutamine = 150 +/- 25 mmHg, P = ns). Dobutamine 9-19 CD59 molecule (CD59 blood group) Homo sapiens 91-96 8717145-6 1996 The mean maximal dobutamine dose was 41,4 +/- 10 mu g/kg center dot min(-1). Dobutamine 17-27 CD59 molecule (CD59 blood group) Homo sapiens 68-74 7621647-4 1995 During infusion of dobutamine up to 40 micrograms kg-1 min-1, arterial pressure was maintained near baseline levels, whereas heart rate and cardiac index increased, more so in group 1 (mean: 89 and 79%) than in group 2 (58 and 52%; P < 0.05 vs. group 1). Dobutamine 19-29 CD59 molecule (CD59 blood group) Homo sapiens 55-60 8582395-8 1995 During dobutamine infusion, exercise resulted in a further increase in heart rate from 108 +/- 11 to 122 +/- 17 mmHg (P < 0.05), in cardiac output from 7.4 +/- 0.9 to 10.3 +/- 2.5 l.min-1 (P < 0.05), and in left ventricular dP/dtmax from 2181 +/- 220 to 2620 +/- 214 mmHg.s-1 (P < 0.05). Dobutamine 7-17 CD59 molecule (CD59 blood group) Homo sapiens 185-190 7574946-3 1995 Dobutamine infusion was started at a rate of 5 micrograms.kg-1.min-2 and increased to 10 and 20 micrograms.kg-1.min-2 at 15-minute intervals. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 63-68 7554756-9 1995 An exercise load of 50 W and a dobutamine infusion of 15 micrograms min-1 kg-1 gave the following results respectively: heart rate, 120.3 +/- 3.0 beats/min versus 110.2 +/- 3.0 beats/min; SD, 16.0 +/- 1.1 ms versus 16.3 +/- 2.5 ms; low-frequency component, 4.3 +/- 0.3 ln-ms2 versus 4.4 +/- 0.3 ln-ms2 and high-frequency component, 2.6 +/- 0.3 ln-ms2 versus 2.2 +/- 0.3 ln-ms2. Dobutamine 31-41 CD59 molecule (CD59 blood group) Homo sapiens 68-78 8262081-4 1993 Seven CHF patients received a continuous intravenous infusion of dobutamine (5 micrograms.kg-1 x min-1) for 96 h. Blood samples were obtained before and every 24 h after starting the therapy. Dobutamine 65-75 CD59 molecule (CD59 blood group) Homo sapiens 97-102 7718371-3 1995 We measured changes in gastric intramucosal pH, splanchnic blood flow and oxygen transport in response to increased systemic flow induced by dobutamine (mean 4.4 (range 3.0-7.0) micrograms kg-1 min-1) after coronary artery bypass. Dobutamine 141-151 CD59 molecule (CD59 blood group) Homo sapiens 194-199 7826649-7 1994 By avoiding volume overload (CVP < or = 10 mmHg) at weaning off ECC and by lowering the systemic vascular resistance and, thus, LV afterload (approximately 8 micrograms.kg-1 min-1 dobutamine), the LV developed systemic pressure (70 +/- 7 vs. 41 +/- 4 mmHg) at unchanged diastolic LV end-diastolic pressure (LVedP) (10 +/- 3 mmHg). Dobutamine 183-193 CD59 molecule (CD59 blood group) Homo sapiens 177-182 8005123-9 1994 Peak rate-pressure product during steady-state dobutamine infusion (18.493 +/- 4.315 mmHg.min-1) was significantly lower (P < 0.01) than during EST (21.316 +/- 4.937 mmHg.min-1). Dobutamine 47-57 CD59 molecule (CD59 blood group) Homo sapiens 90-95 1389847-2 1992 Nine healthy, adult, non-obese, male physicians were infused with an incremental infusion of dobutamine starting at 2.5 micrograms kg-1 min-1 increasing to 5.0 and then 7.5 micrograms kg-1 min-1 for 15 min each. Dobutamine 93-103 CD59 molecule (CD59 blood group) Homo sapiens 136-141 1325107-3 1992 After a left main intracoronary infusion of dobutamine (25 to 200 micrograms.min-1), beta-adrenergic contractile responsiveness was assessed as the net increase in peak positive LV dp/dt (delta LV dp/dt). Dobutamine 44-54 CD59 molecule (CD59 blood group) Homo sapiens 77-82 8508864-9 1993 Dobutamine also significantly increased heart rate from a mean of 108 beats.min-1 to 117 beats.min-1 (P < 0.001). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 76-81 8508864-9 1993 Dobutamine also significantly increased heart rate from a mean of 108 beats.min-1 to 117 beats.min-1 (P < 0.001). Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 95-100 8491224-7 1993 Fourteen patients were able to tolerate dobutamine 20 micrograms kg-1 min-1. Dobutamine 40-50 CD59 molecule (CD59 blood group) Homo sapiens 70-75 1466438-1 1992 The report describes a patient during induction of anaesthesia for coronary artery by-pass grafting, in whom the infusion of dobutamine at a rate of 5 micrograms.kg-1.min-1 resulted in unanticipated severe hypertension. Dobutamine 125-135 CD59 molecule (CD59 blood group) Homo sapiens 167-172 1412379-5 1992 There is a significant increase in coronary bypass flow induced by both rates of 0.4 and 0.8 microgram x kg-1 x min-1 dobutamine, but there was no significant effect on bypass flow induced by dopamine. Dobutamine 118-128 CD59 molecule (CD59 blood group) Homo sapiens 112-117 1412379-8 1992 A significant increase in rate of contraction and relaxation was only induced by the higher dosage of 0.8 microgram x kg-1 x min-1 dobutamine. Dobutamine 131-141 CD59 molecule (CD59 blood group) Homo sapiens 125-130 1577035-2 1992 Dobutamine was infused at incremental doses (up to a maximum of 40 micrograms kg-1 min-1) in 52 patients with chest pain; all the patients underwent coronary angiography; significant coronary artery disease was quantitatively defined as greater than or equal to 50% diameter stenosis. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 83-88 1310921-4 1992 The energy expenditure increased and was 33% higher than control (P less than 0.001) at 10 micrograms of dobutamine min-1 kg-1. Dobutamine 105-115 CD59 molecule (CD59 blood group) Homo sapiens 116-126 1310921-5 1992 The respiratory exchange ratio decreased from 0.85 (SEM 0.02) before infusion to 0.80 (SEM 0.01) at 10 micrograms of dobutamine min-1 kg-1, but did not alter during the placebo infusion (P less than 0.001). Dobutamine 117-127 CD59 molecule (CD59 blood group) Homo sapiens 128-138 1310921-11 1992 The plasma insulin concentration increased at 2 and 5 micrograms of dobutamine min-1 kg-1 (P less than 0.001) with no further rise at 10 micrograms of dobutamine min-1 kg-1. Dobutamine 68-78 CD59 molecule (CD59 blood group) Homo sapiens 79-89 1676248-9 1991 Cardiovascular collapse was treated with dobutamine (10 micrograms.kg-1.min-1). Dobutamine 41-51 CD59 molecule (CD59 blood group) Homo sapiens 72-77 1655438-2 1991 For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1. Dobutamine 68-78 CD59 molecule (CD59 blood group) Homo sapiens 132-137 1655438-2 1991 For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1. Dobutamine 68-78 CD59 molecule (CD59 blood group) Homo sapiens 182-187 1655438-2 1991 For this purpose, a four-point dose-response curve was prepared for dobutamine starting with an initial dose of 2.5 micrograms kg-1 min-1, which was increased by 2.5 micrograms kg-1 min-1 at a time up to altogether 10 micrograms kg-1 min-1. Dobutamine 68-78 CD59 molecule (CD59 blood group) Homo sapiens 182-187 2318228-2 1990 Dobutamine-ECG test (dose of 5, 10, 15 and 20 micrograms kg-1 min-1 every 5 min) was performed 5 to 12 days after the beginning of the symptoms of AMI, and coronary angiography within the first month. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 62-67 1833898-6 1991 Dobutamine was administered in a dose of 4-7 micrograms.kg-1.min-1 over the same period. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 61-66 2248392-1 1990 Using implanted pulsed Doppler microprobes sutured on saphenous bypass grafts in ten patients we studied, 6 h after cardiac surgery, the effects of 5 and 10 micrograms.kg-1.min-1 of dobutamine on mean (Qm), systolic (Qs), and diastolic (Qd) coronary bypass graft flows, as well as on coronary systolic (integral of Qs) and diastolic (integral of Qd) blood volumes entering the myocardium per cardiac beat. Dobutamine 182-192 CD59 molecule (CD59 blood group) Homo sapiens 173-178 2544635-7 1989 Both drugs similarly increased cardiac output: +2.61.min-1 +/- 1.4 for DP and 2.21.min-1 +/- 1.5 for DB. Dobutamine 101-103 CD59 molecule (CD59 blood group) Homo sapiens 83-88 2358560-5 1990 During combined fentanyl-midazolam and clonidine infusion, cardiovascular depression gradually developed over several days necessitating the institution of a dobutamine infusion (dose: 8-12 micrograms kg-1 min-1). Dobutamine 158-168 CD59 molecule (CD59 blood group) Homo sapiens 206-211 2679978-7 1989 Forty-five patients were infused dobutamine 7 micrograms.kg-1.min-1 (group D) from 10 min. Dobutamine 33-43 CD59 molecule (CD59 blood group) Homo sapiens 62-67 2679978-13 1989 With dobutamine, haemodynamic parameters returned to preoperative values and heart rate increased by 12 b.min-1. Dobutamine 5-15 CD59 molecule (CD59 blood group) Homo sapiens 106-111 2712404-4 1989 The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders. Dobutamine 57-67 CD59 molecule (CD59 blood group) Homo sapiens 51-56 2712404-4 1989 The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders. Dobutamine 57-67 CD59 molecule (CD59 blood group) Homo sapiens 102-107 2712404-4 1989 The administration of 10.6 +/- 0.5 micrograms.kg-1.min-1 dobutamine (starting dose: 6 micrograms.kg-1.min-1) was started when the cardiac index (CI) was less than 3.3 l.min-1.m-2 after vascular filling with plasma expanders. Dobutamine 57-67 CD59 molecule (CD59 blood group) Homo sapiens 102-107 6705283-3 1984 Each patient underwent a continuous infusion of dobutamine from 2.5 to 10 micrograms/kg min-1 with dosage increments of 2.5 micrograms/kg at 15-minute intervals. Dobutamine 48-58 CD59 molecule (CD59 blood group) Homo sapiens 88-93 3446365-3 1987 When dobutamine was infused at 10 micrograms.kg-1.min-1 seven out of 10 patients had power output values above the defined limits, implying that the technique can identify correctly in vivo the direct positive inotropic effects of dobutamine in the presence of its vasodilating activity. Dobutamine 5-15 CD59 molecule (CD59 blood group) Homo sapiens 50-55 3446365-3 1987 When dobutamine was infused at 10 micrograms.kg-1.min-1 seven out of 10 patients had power output values above the defined limits, implying that the technique can identify correctly in vivo the direct positive inotropic effects of dobutamine in the presence of its vasodilating activity. Dobutamine 231-241 CD59 molecule (CD59 blood group) Homo sapiens 50-55 6705283-8 1984 However, 5 patients showed a decreased myocardial lactate extraction after 10 micrograms/kg min-1 of intravenous dobutamine, 3 from group I and 2 from group II. Dobutamine 113-123 CD59 molecule (CD59 blood group) Homo sapiens 92-97 649837-2 1978 The dosage of dobutamine started from 2.5 mcg kg-1 min-1 and was increased stepwise to 5, 7.5, 10, 12.5 and 15 mcg kg-1 min-1. Dobutamine 14-24 CD59 molecule (CD59 blood group) Homo sapiens 51-56 649837-2 1978 The dosage of dobutamine started from 2.5 mcg kg-1 min-1 and was increased stepwise to 5, 7.5, 10, 12.5 and 15 mcg kg-1 min-1. Dobutamine 14-24 CD59 molecule (CD59 blood group) Homo sapiens 120-125 649837-13 1978 We conclude that in patients with depressed cardiac function dobutamine at low doses of 2.5 mcg kg-1 min-1 decreases afterload and filling pressures. Dobutamine 61-71 CD59 molecule (CD59 blood group) Homo sapiens 101-106 35061-3 1978 Doses of dobutamine of 5 or 7.5 microgram.kg-1.min-1 corrected the IC, PCP and TPR. Dobutamine 9-19 CD59 molecule (CD59 blood group) Homo sapiens 47-52 35061-4 1978 Dobutamine ameliorated the SI and SWILV in an increasing fashion up to a dose of 10 microgram.kg-1.min-1 only and without restoring them to the control values of the pre-operative period. Dobutamine 0-10 CD59 molecule (CD59 blood group) Homo sapiens 99-104 35061-7 1978 Tests of vascular filling (pre-charge tests) carried out in the second group of patients under 10 microgram,kg-1.min-1 of dobutamine and in a third group under 15 microgram.kg-1.min-1 showed a good cardiac adaptation to filling, equal or superior to that of the pre-operative period. Dobutamine 122-132 CD59 molecule (CD59 blood group) Homo sapiens 113-118 35061-8 1978 It also appeared that the amelioration of CF obtained with a moderate vascular filling (300 ml of low molecular weight dextran) under 10 microgram.kg-1.min-1 of dobutamine is greatly superior to the amelioration obtained by 10 to 15 microgram.kg-1.min-1 of dobutamine. Dobutamine 161-171 CD59 molecule (CD59 blood group) Homo sapiens 152-157